The efficacy of VMD-928 is currently being evaluated in patients with various cancers that overexpress TrkA (adenoid cystic carcinoma, cholangiocarcinoma, lung cancer, pancreatic cancer, parotid gland cancer and squamous cell carcinoma of the head and neck; Phase I clinical trial) [71]. This evidence concerns the gene NTRK1 and cancer.